Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous blood is a biological substance used as an endoscopic hemostatic agent for the management of actively bleeding gastroduodenal ulcers. In this clinical procedure, 5-20 cc of the patient's own blood is withdrawn and immediately injected into the submucosa at the edges of the ulcer. The therapeutic effect is achieved through mechanical tamponade, which compresses the bleeding vessel, and the localized activation of the coagulation cascade to form a stable fibrin clot. This technique has been investigated by Zagazig University in randomized controlled trials as an alternative to epinephrine injection, aiming to provide effective hemostasis while avoiding the systemic cardiovascular side effects associated with sympathomimetic agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous blood.